Mometasone is a corticosteroid demonstrating anti-inflammatory properties. The precise mechanism of corticosteroids action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.

Momeson Nasal Spray is indicated for the treatment and prophylaxis of the nasal symptoms of seasonal allergic rhinitis and for the prophylaxis of the nasal symptoms of perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. It is also indicated for the treatment of nasal polyps in patients 18 years of age and older.

Allergic Rhinitis :
Adults and Children 12 Years of Age and Older : The recommended dose for prophylaxis and treatment of the nasal symptoms of seasonal allergic rhinitis and treatment of the nasal symptoms of perennial allergic rhinitis is 2 sprays in each nostril once daily. In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with Momeson Nasal Spray is recommended 2 to 4 weeks prior to the anticipated start of the pollen season.
Children 2 to 11 Years of Age : The recommended dose for treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis is 1 spray in each nostril once daily

Nasal Polyps : Adults 18 years of Age and Older: The recommended dose for nasal polyps is 2 sprays in each nostril twice daily. A dose of 2 sprays in each nostril once daily is also effective in some patients.

Generally side effects are mild and included headache, viral infection, sore throat, nosebleeds and coughing.

Use with caution in active or inactive tuberculosis infection, herpes simplex virus infection of the eye, untreated infections affecting the body as a whole etc.

Hypersensitivity to any of the ingredients of this preparation contraindicates its use.

Pregnancy : There are no adequate and well-controlled studies in pregnant women. Mometasone Furoate, like other corticosteroids should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.
Lactation : It is not known if Mometasone Furoate is excreted in human milk. Since other corticosteroids are excreted in human milk, caution should be used when Mometasone Furoate is administered to nursing women.

There are no drug interactions of note with Mometasone Furoate.

There are no data available on the effects of acute or chronic over dosage with Mometasone Furoate. Because of low systemic bioavailability, and an absence of acute drug-related systemic findings in clinical studies, overdose is unlikely to require any therapy other than observation.

Momeson Nasal Spray : Each bottle contains 120-metered doses for spray.